BioCryst Pharmaceuticals Gestion
Gestion contrôle des critères 1/4
Le PDG BioCryst Pharmaceuticals est Charlie Gayer, nommé en Aug2025, a un mandat de 1.08 ans. La rémunération annuelle totale est $ 9.63M, composée du salaire de 6.3% et des bonus 93.7%, y compris les actions et options de la société. détient directement 0.14% des actions de la société, d'une valeur de $ 3.16M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.2 ans et 5 ans.
Informations clés
Charlie Gayer
Directeur général
US$9.6m
Rémunération totale
| Pourcentage du salaire du PDG | 6.33% |
| Durée du mandat du directeur général | 1.1yrs |
| Propriété du PDG | 0.1% |
| Durée moyenne d'occupation des postes de direction | 1.2yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 5yrs |
Mises à jour récentes de la gestion
Recent updates
Seeking Alpha • Sep 11
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity
Summary BioCryst Pharmaceuticals, Inc.'s shares remain under pressure. At the same time, Orladeyo revenue increased 6.7% QoQ to $158.2 million in the second quarter. BioCryst's royalty financing obligations declined from $465.7 million at the end of Q4 2025 to $426.8 million at the end of June. I also believe BioCryst made a smart move by acquiring navenibart, an investigational therapy for HAE. With 149%upside to the average analyst price target, I believe BCRX stock presents an attractive risk/reward profile. Read the full article on Seeking Alpha
Mise à jour du récit • Sep 10
BCRX: Navenibart Execution Will Drive Future Upside Despite Orladeyo Headwinds
BioCryst Pharmaceuticals' analyst fair value has been revised from $12.00 to $11.00, as analysts factor in a higher discount rate, a softer revenue outlook tied to potential Orladeyo switching, and updated P/E and margin assumptions that reflect a more balanced view of near term risks and longer term opportunities around navenibart. Analyst Commentary Recent Street research on BioCryst Pharmaceuticals points to a more cautious tone, especially around the durability of Orladeyo revenues and the execution risk tied to navenibart.Mise à jour du récit • Jul 22
BCRX: Navenibart-Focused Rare Disease Model Will Drive Long Term Upside Potential
Analysts have lowered the fair value estimate for BioCryst Pharmaceuticals to $12.00 from $14.00, citing a slightly higher discount rate, some pressure on projected profit margins, and the view that upside now leans more heavily on the success of the navenibart launch, even as firms offer supportive commentary on the long-term potential of its hereditary angioedema franchise and possible M&A interest. Analyst Commentary Recent research on BioCryst Pharmaceuticals highlights a mixed backdrop, with attention firmly on navenibart and the hereditary angioedema portfolio.Mise à jour du récit • Jul 07
BCRX: Rare Disease Deal Interest Will Support Long Term Upside Potential
Analysts have lifted their fair value estimate for BioCryst Pharmaceuticals from $13.00 to $14.00 per share, citing higher assumed long term profit margins and ongoing interest in rare disease stocks following recent sector M&A activity and increased Street price targets, including the move to $29.00 at Cantor Fitzgerald. Analyst Commentary Recent Street research around BioCryst Pharmaceuticals has centered on how the stock fits into a broader wave of rare disease M&A and what that might mean for its valuation and execution risks.
Mise à jour du récit • Jun 17
BCRX: Rare Disease Pipeline Progress And Licensing Deal Will Drive Shares
BioCryst Pharmaceuticals saw its consensus analyst price target raised by a few dollars into the mid $30s, as analysts pointed to updated assumptions around revenue growth, profit margins, and future P/E multiples to support their revised valuation work. Analyst Commentary Bullish analysts covering BioCryst Pharmaceuticals have recently adjusted their models and raised price targets, reflecting updated views on revenue growth assumptions, profit margins, and the P/E multiples they are willing to apply to the stock.Article d’analyse • Jun 16
BioCryst (BCRX) Stock After New HAE Data Presentation Is The Undervaluation Story Still Intact
BioCryst Pharmaceuticals (BCRX) drew investor attention after presenting new clinical and real world data on its hereditary angioedema therapies ORLADEYO and navenibart at the European Academy of Allergy and Clinical Immunology meeting in Istanbul. See our latest analysis for BioCryst Pharmaceuticals. At a share price of US$9.06, BioCryst has seen short term momentum pick up around the EAACI data, with a 1 day share price return of 4.14% and year to date share price return of 20.80%. However,...
Mise à jour du récit • Jun 02
BCRX: HAE Portfolio Progress And European Deal Will Support Upside
Analysts have nudged their price targets on BioCryst Pharmaceuticals higher, with recent Street research pointing to a combined $4 increase as they update assumptions on revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts point to updates in revenue assumptions as a key driver behind the combined US$4 increase in price targets, suggesting more confidence in the company’s ability to translate its pipeline and products into higher sales over time.Mise à jour du récit • May 16
BCRX: Astria Integration And Licensing Deal Will Support Hereditary Angioedema Expansion
Analysts have nudged their average price target on BioCryst higher by low single digits in recent weeks, citing reiterated long-term revenue goals following the Astria Therapeutics acquisition, ongoing confidence in Orladeyo and navenibart sales potential, and steadier expectations for future profitability and P/E levels. Analyst Commentary Recent research has leaned constructive on BioCryst, with several bullish analysts adjusting their price targets upward and reaffirming confidence in the company’s long term revenue framework following the Astria Therapeutics acquisition.Mise à jour du récit • May 01
BCRX: Astria Deal And FY26 Goals Will Support Rare Disease Upside
Analysts have inched their average price target on BioCryst Pharmaceuticals higher by $0.10 to $21.40, reflecting research that points to steady commercial execution, reiterated long term revenue goals following the Astria Therapeutics acquisition, and continued interest in the BCX17725 program as well as Orladeyo and navenibart sales potential. Analyst Commentary Recent research highlights a mix of enthusiasm and caution around BioCryst, with price targets edging higher and coverage resuming as analysts digest the Astria Therapeutics acquisition, updated guidance, and the company’s rare disease portfolio.Mise à jour du récit • Apr 17
BCRX: Astria Integration And 2031 Debt Structure Will Support Hereditary Angioedema Expansion
Narrative Update Analysts have nudged their price targets on BioCryst Pharmaceuticals higher by $1. This reflects continued confidence in management's reiterated FY26 guidance, the integration of the Astria Therapeutics acquisition, and the longer term potential they see in Orladeyo and navenibart.Mise à jour du récit • Apr 03
BCRX: Astria Acquisition And FY26 Guidance Will Support Long-Term Revenue Potential
Analysts lifted their price target on BioCryst Pharmaceuticals to $22 from $21, citing steady forward guidance, reaffirmed peak revenue goals following the Astria Therapeutics acquisition, and confidence in Orladeyo and the BCX17725 program as key factors supporting the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as supported by reiterated FY26 guidance and peak revenue goals, which they view as evidence that management is confident in the current growth plan.Mise à jour du récit • Mar 20
BCRX: Astria Acquisition And FY26 Outlook Will Support Long Term Upside
Analysts lifted their price targets on BioCryst to a range of $17 to $22, citing steady FY26 guidance, reaffirmed peak revenue goals, and confidence in the Astria Therapeutics acquisition and BCX17725 data timeline as key supports for the higher valuations. Analyst Commentary Recent Street research on BioCryst highlights a mix of optimism around the Astria Therapeutics acquisition, reaffirmed FY26 guidance, and the commercial trajectory of Orladeyo, alongside growing interest in the BCX17725 program as a potential long term driver.Mise à jour du récit • Mar 05
BCRX: Astria Acquisition And FY26 Outlook Will Support Long-Term HAE Leadership
Analysts have raised their blended price target on BioCryst Pharmaceuticals to about $21.30 from $20.50, citing reaffirmed FY26 guidance, reiterated peak revenue goals after the Astria Therapeutics acquisition, and continued confidence in the commercial ramp and the BCX17725 data timeline. Analyst Commentary Bullish Takeaways Bullish analysts see the higher blended price targets, up to about $22, as reflecting confidence in execution on the FY26 guidance and the longer term revenue framework.Mise à jour du récit • Feb 19
BCRX: Astria Acquisition Will Drive Hereditary Angioedema Franchise Expansion
Analysts have reaffirmed their $32.00 fair value estimate for BioCryst Pharmaceuticals and supported a $17.00 price target, citing expectations for Orladeyo to potentially reach $900m in sales by 2029 and for navenibart to approach $1b in risk adjusted sales following the Astria Therapeutics acquisition. Analyst Commentary Bullish analysts view the reaffirmed US$32.00 fair value estimate and the US$17.00 price target as grounded in a clearer revenue roadmap, with both Orladeyo and navenibart framed as key building blocks of the story rather than optional upside.Mise à jour du récit • Feb 05
BCRX: Pediatric Approval And 2031 Financing Will Strengthen Long Term Outlook
Narrative Update Overview Analysts have raised their price target on BioCryst Pharmaceuticals from US$11.00 to US$13.00, reflecting updated assumptions on revenue, profit margins, discount rate and future P/E multiples in their valuation work. What's in the News Entered a new loan agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. for term loans with gross proceeds of US$400 million, issued in multiple tranches and maturing on January 23, 2031, with quarterly interest-only payments and principal due at maturity (company announcement).Mise à jour du récit • Jan 22
BCRX: Pediatric Expansion And 2025 Profitability Outlook Will Support Long-Term HAE Leadership
Narrative Update Overview Analysts now see fair value for BioCryst Pharmaceuticals at US$20.50 per share, a US$0.10 adjustment that reflects updated assumptions on revenue growth, profit margins, discount rate, and future P/E levels. What's in the News BioCryst issued full year 2026 earnings guidance, with total revenue expected in a range of US$635 million to US$660 million (company guidance).Mise à jour du récit • Jan 08
BCRX: Astria Acquisition Will Extend HAE Leadership With Long Acting Injectable Through 2042
Narrative Update: BioCryst Pharmaceuticals The updated analyst price target for BioCryst Pharmaceuticals has moved modestly higher to about $20.60 from $20.40, with analysts pointing to the planned $700m acquisition of Astria Therapeutics, expected SG&A synergies, and the potential of HAE candidate navenibart to support BioCryst's hereditary angioedema franchise as key reasons for their revised view. Analyst Commentary Street research around BioCryst's planned US$700m acquisition of Astria Therapeutics clusters around the same core themes, but with different levels of enthusiasm about execution risk, competitive pressure, and valuation.Mise à jour du récit • Dec 24
BCRX: Astria Acquisition Will Extend Hereditary Angioedema Leadership Through Navenibart
We raise our BioCryst Pharmaceuticals fair value estimate to $32.00 from $28.15, as analysts highlight the accretive $700M Astria Therapeutics acquisition and its potential to extend the company’s hereditary angioedema leadership with long acting navenibart through the next decade. Analyst Commentary Analysts with a positive view on the stock are broadly endorsing BioCryst's acquisition of Astria Therapeutics, describing it as a value-accretive move that enhances the company’s hereditary angioedema portfolio and extends its potential growth runway into the 2030s and beyond.Mise à jour du récit • Dec 10
BCRX: Astria Acquisition Will Extend HAE Leadership With Long-Acting Injectable Through 2042
Analysts have lifted their average price targets on BioCryst Pharmaceuticals by a mid-teens dollar amount into the mid to high $20s per share range, citing the proposed $700M acquisition of Astria Therapeutics as a strategically sound, earnings-accretive move that extends the company’s hereditary angioedema leadership and reduces long-term growth risk. Analyst Commentary Street research following the Astria Therapeutics deal skews constructive, with most price target revisions reflecting higher confidence in BioCryst’s long term growth profile and durability in hereditary angioedema, even as investors weigh near term dilution and competitive risks.Mise à jour du récit • Nov 26
BCRX: Acquisition Will Extend HAE Franchise With New Long-Acting Candidate Through 2042
BioCryst Pharmaceuticals’ fair value estimate has increased from $19.73 to $20.40 per share. Analysts cite the company’s acquisition of Astria Therapeutics and improved long-term growth prospects following recent price target raises by multiple firms.Mise à jour du récit • Nov 12
BCRX: Acquisition Will Drive Earnings Upside With New HAE Candidate Through 2042
BioCryst Pharmaceuticals' fair value estimate has been adjusted downward by approximately $0.55 per share, as analysts incorporate the strategic rationale and expected synergies following the announced acquisition of Astria Therapeutics. Analyst Commentary Market observers have provided a range of insights following BioCryst Pharmaceuticals' acquisition of Astria Therapeutics.Article d’analyse • Nov 06
Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Last week saw the newest third-quarter earnings release from BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ), an...Mise à jour du récit • Oct 29
Acquisition Of Leading HAE Therapy Candidate Will Drive Future Market Expansion
Analysts have raised their price target for BioCryst Pharmaceuticals from $18.50 to approximately $20.27 per share. This change reflects optimism about the company's acquisition of Astria Therapeutics and its anticipated impact on future growth and market position.Mise à jour du récit • Oct 14
Expanding Rare Disease Pipeline Will Open New Markets
Analysts have raised their fair value estimate for BioCryst Pharmaceuticals to $18.50 from $16.73. They cited the anticipated long-term benefits and strategic alignment from the recent Astria Therapeutics acquisition, despite some near-term uncertainties.Article d’analyse • Aug 07
BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
A week ago, BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) came out with a strong set of quarterly numbers that could...Nouveau récit • May 09
ORLADEYO Pipeline Will Deliver New Therapeutic Opportunities
ORLADEYO's revenue growth, patient conversion, and reduced royalty payments enhance profitability, cash flow, and financial stability for BioCryst Pharmaceuticals.Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$385m |
| Mar 31 2026 | n/a | n/a | -US$458m |
| Dec 31 2025 | US$10m | US$609k | US$264m |
| Sep 30 2025 | n/a | n/a | -US$9m |
| Jun 30 2025 | n/a | n/a | -US$36m |
| Mar 31 2025 | n/a | n/a | -US$53m |
| Dec 31 2024 | US$3m | US$545k | -US$89m |
| Sep 30 2024 | n/a | n/a | -US$124m |
| Jun 30 2024 | n/a | n/a | -US$146m |
| Mar 31 2024 | n/a | n/a | -US$209m |
| Dec 31 2023 | US$2m | US$495k | -US$227m |
| Sep 30 2023 | n/a | n/a | -US$236m |
| Jun 30 2023 | n/a | n/a | -US$243m |
| Mar 31 2023 | n/a | n/a | -US$226m |
| Dec 31 2022 | US$2m | US$449k | -US$247m |
Rémunération vs marché: La rémunération totale de Charlie ($USD 9.63M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 5.29M ).
Rémunération et revenus: La rémunération de Charlie a augmenté alors que l'entreprise n'est pas rentable.
PDG
Charlie Gayer (55 yo)
1.1yrs
Titularisation
US$9,627,868
Compensation
Mr. Charles K. Gayer, also known as Charlie, is President at BioCryst Pharmaceuticals, Inc. since August 1, 2025 and serves as its Chief Executive Officer & Director since January 01, 2026. He served as th...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 1.1yrs | US$9.63m | 0.14% $ 3.2m | |
| CFO & Head of Corporate Development | 1.2yrs | US$6.75m | pas de données | |
| Senior VP | 20yrs | US$5.62m | 0.058% $ 1.3m | |
| Chief Technical Operations Officer | less than a year | pas de données | pas de données | |
| Chief Scientific Officer | less than a year | pas de données | pas de données | |
| Manager of Investor Relations | no data | pas de données | pas de données | |
| Chief People Officer & Communications Officer | 1.1yrs | pas de données | pas de données | |
| Chief Development Officer | 18.2yrs | US$2.66m | pas de données | |
| Chief Discovery Officer | 12.9yrs | US$2.57m | pas de données | |
| Chief Data Innovation Officer | 4.8yrs | pas de données | pas de données | |
| Chief Strategy Officer | 4yrs | pas de données | pas de données | |
| Chief Commercial Officer | less than a year | pas de données | 0.020% $ 447.6k |
1.2yrs
Durée moyenne de l'emploi
61.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de BCRX n'est pas considérée comme expérimentée (ancienneté moyenne 1.2 ans), ce qui suggère une nouvelle équipe.
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$9.63m | 0.14% $ 3.2m | |
| Independent Chairman | 5.2yrs | US$403.70k | 0.037% $ 818.9k | |
| Independent Director | 6.6yrs | US$397.50k | 0.020% $ 449.4k | |
| Independent Director | 1.3yrs | US$396.49k | 0.0079% $ 175.4k | |
| Independent Director | less than a year | pas de données | 0.0022% $ 49.0k | |
| Independent Director | 7.8yrs | US$401.70k | 0.021% $ 458.7k | |
| Director | 19.7yrs | US$12.95m | 0.41% $ 9.0m | |
| Independent Director | 5yrs | US$385.58k | 0.023% $ 506.6k | |
| Independent Director | 4.6yrs | US$385.25k | 0.0071% $ 157.5k | |
| Independent Director | 5yrs | US$390.00k | 0.013% $ 282.4k |
5.0yrs
Durée moyenne de l'emploi
63.5yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de BCRX sont considérés comme expérimentés (ancienneté moyenne 5 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/21 04:37 |
| Cours de l'action en fin de journée | 2026/09/21 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
BioCryst Pharmaceuticals, Inc. est couverte par 27 analystes. 10 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Steven Seedhouse | Cantor Fitzgerald & Co. |